The DOI matches its Crossref record, with a small difference in title or year; 87 of the 87 references it cites were found in a registry or an index.
NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes
Abstract
In Brief Background: This review summarizes the data reported in peer-reviewed literature and presents current knowledge on differentiation, natural history, and therapeutic outcomes of neovascular age-related macular degeneration (AMD). Methods: The MEDLINE database was searched to review natural history of neovascular AMD and therapeutic effects of available treatments. Results: The search produced >7,000 articles. Research suggests that fluorescein angiographic characterization of location, composition, and size of neovascular lesions may be important in prognosis and should be considered for evaluation of treatment benefits in conjunction with evidence of recent disease progression for lesions not composed of predominantly classic choroidal neovascularization (CNV). Laser photocoagulation, photodynamic therapy with verteporfin, and administration of pegaptanib sodium reduce the risk of vision loss in selected cases of neovascular AMD, while submacular surgery can reduce the risk of severe visual acuity loss in selected cases of predominantly hemorrhagic CNV; further approaches are under investigation. Conclusion: Visual prognosis of neovascular AMD is variable according to lesion location, composition, and size. Often, lesions have a poor prognosis, resulting in rapid and progressive loss of visual acuity and contrast sensitivity. Such losses have a profound effect on patients' quality of life and ability to perform everyday tasks. Reducing the risk of further loss of visual acuity and contrast sensitivity might enable patients with neovascular AMD to maintain better functional abilities. Understanding the natural history of neovascular age-related macular degeneration and visual prognosis associated with angiographic features may help define meaningful treatment benefits. Laser photocoagulation, photodynamic therapy with verteporfin, submacular surgery, and administration of pegaptanib sodium reduce vision loss in selected cases. This review will be a useful source of information for retina specialists and general ophthalmologists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subretinal and retinal scarring are associated with profound vision loss and are natural outcomes of neovascular age-related macular degeneration (nvAMD).1–4”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [4]
Citations
Cites
1 retracted
TOLENTINO, M. J., BRUCKER, A. J., FOSNOT, J., YING, G.-S., WU, I.-H., MALIK, G., WAN, S., & REICH, S. J. (2004) · RETINA · doi:10.1097/00006982-200402000-00018 · Cited by 172
RetractedPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
Thylefors, B., Négrel, A. D., Pararajasegaram, R., & Dadzie, K. Y. (1995) · Europe PMC (PubMed Central) · Cited by 1,292
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Klaver, C. C. W. (1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.5.653 · Cited by 881
(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Visual Acuity and the Causes of Visual Loss in Australia
Attebo, K., Mitchell, P., & Smith, W. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30684-2 · Cited by 795
Research works printed but not linked: 9
- Klein, 1995, Invest Ophthalmol Vis Sci, 36, 182
- Thylefors, 1995, Bull World Health Organ, 73, 115
- Coscas, 1983, Bull Mem Soc Fr Ophtalmol, 94, 149
- 2001, Arch Ophthalmol, 119, 198
- Walsh, 1989, Ann Ophthalmol, 21, 348
- Stein, 2003, Br J Ophthalmol, 87, 8, 10.1136/bjo.87.1.8 · DOI
- Rubin, 1994, Optom Vis Sci, 71, 750, 10.1097/00006324-199412000-00005 · doi:10.1097/00006324-199412000-00005
- Rubin, 2001, Invest Ophthalmol Vis Sci, 42, 64
- 2003, Ophthalmology, 110, 2372, 10.1016/j.ophtha.2003.08.020 · DOI · Paper page
Cited by
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
Metadata
- Authors
- Pauleikhoff, D.
- Affiliations
- St. Franziskus Hospital (DE)
- Corresponding author
- Pauleikhoff, Daniel
- ORCID
- Pauleikhoff, Daniel
- Venue
- Retina
- Published
- 2005-12
- Volume
- 25
- Issue
- 8
- Pages
- 1065-1084
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2031734192
- Cited by
- 108
- References
- 87
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 10 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 5 · 2015: 5 · 2014: 3 · 2013: 7 · 2012: 6
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, natural history (disease), visual prognosis, fluorescein angiography, laser photocoagulation, photodynamic therapy, verteporfin, pegaptanib sodium, submacular surgery, visual acuity loss, contrast sensitivity
- MeSH terms
- Fluorescein Angiography, Humans, Macular Degeneration, Photochemotherapy, Prognosis, Visual Acuity, Treatment Outcome, Laser Coagulation, Choroidal Neovascularization, Aptamers, Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes. https://app.cochat.ai/papers/10.1097/00006982-200512000-00016
- The paper
- Pauleikhoff, D. (2005). NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes. Retina. https://doi.org/10.1097/00006982-200512000-00016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.